On the other hand, a study that used publicly available microarray data-sets, deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) demonstrated that the association between RANTES and overall survival (OS) among ovarian cancer patients was dependent on the TP53 mutation status and higher expression of RANTES was associated with better OS only on TP53 mutant serous ovarian cancer [65]. This evidence concerns the gene TP53 and ovarian serous adenocarcinoma.